Discovers, develops and commercializes novel products for the treatment of cancer
Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer.
The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types.
It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers.
Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA.